{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:47:43Z","timestamp":1791906463647,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.trecan.2026.07.010","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:42:36Z","timestamp":1787312556000},"page":"892-894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drugging the undruggable: early phase trial shows trabectedin and low-dose irinotecan downregulate EWSR1::FLI1 and has clinical activity in advanced Ewing sarcoma"],"prefix":"10.1016","volume":"12","author":[{"given":"David S.","family":"Shulman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6000-3594","authenticated-orcid":false,"given":"Katherine A.","family":"Janeway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.07.010_bb0005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMra2028910","article-title":"Ewing\u2019s sarcoma","volume":"384","author":"Riggi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.07.010_bb0010","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa020890","article-title":"Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor of bone","volume":"348","author":"Grier","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.07.010_bb0015","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children\u2019s Oncology Group","volume":"30","author":"Womer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.010_bb0020","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(22)01790-1","article-title":"Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial","volume":"400","author":"Brennan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.07.010_bb0025","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1002\/cncr.30627","article-title":"Longitudinal follow-up of adult survivors of Ewing sarcoma: a report from the childhood cancer survivor study","volume":"123","author":"Marina","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.trecan.2026.07.010_bb0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.3489","article-title":"Dose intensification improves the outcome of Ewing sarcoma","author":"Gorlick","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.010_bb0035","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41591-026-04340-7","article-title":"Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1\/2 trial","volume":"32","author":"Grohar","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.07.010_bb0040","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/359162a0","article-title":"Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours","volume":"359","author":"Delattre","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.07.010_bb0045","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jnci\/djae075","article-title":"Targeting fusion oncoproteins in childhood cancers: challenges and future opportunities for developing therapeutics","volume":"116","author":"Verma","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.trecan.2026.07.010_bb0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cell.2017.07.036","article-title":"Cancer-specific retargeting of BAF complexes by a prion-like domain","volume":"171","author":"Boulay","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.07.010_bb0055","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1200\/JCO.24.00020","article-title":"Open-label, multicenter, phase I\/II, first-in-human trial of TK216: a first-generation EWS::FLI1 fusion protein antagonist in Ewing sarcoma","volume":"42","author":"Meyers","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.010_bb0060","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.chembiol.2022.06.002","article-title":"TK216 targets microtubules in Ewing sarcoma cells","volume":"29","author":"Povedano","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.trecan.2026.07.010_bb0065","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/pbc.21822","article-title":"Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children\u2019s Oncology Group","volume":"52","author":"DuBois","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.trecan.2026.07.010_bb0070","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00280-017-3382-x","article-title":"A phase I\/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS\u2013FLI1 fusion transcript","volume":"80","author":"Grohar","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.trecan.2026.07.010_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29333","article-title":"Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: a report from the Children\u2019s Oncology Group","volume":"68","author":"Collier","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.trecan.2026.07.010_bb0080","doi-asserted-by":"crossref","first-page":"LBA2","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA2","article-title":"Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES)","volume":"40","author":"McCabe","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.010_bb0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1593\/neo.101202","article-title":"Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells","volume":"13","author":"Grohar","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.trecan.2026.07.010_bb0090","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/1078-0432.672.11.2","article-title":"A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children\u2019s Oncology Group study","volume":"11","author":"Lau","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.010_bb0095","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ejca.2011.09.027","article-title":"A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children\u2019s Oncology Group","volume":"48","author":"Baruchel","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2026.07.010_bb0100","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1158\/1078-0432.CCR-18-3511","article-title":"Trabectedin inhibits EWS-FLI1 and evicts SWI\/SNF from chromatin in a schedule-dependent manner","volume":"25","author":"Harlow","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.010_bb0105","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1200\/JCO.2008.19.1478","article-title":"Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children\u2019s Oncology Group Study","volume":"27","author":"Granowetter","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.010_bb0110","series-title":"Use of Circulating Tumor DNA for Curative-Intent Solid Tumor Drug Development: Guidance for Industry","author":"Food","year":"2024"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326001676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326001676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:12:05Z","timestamp":1791904325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326001676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2405803326001676"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.07.010","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugging the undruggable: early phase trial shows trabectedin and low-dose irinotecan downregulate EWSR1::FLI1 and has clinical activity in advanced Ewing sarcoma","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}